Medical Device Procurement in China: A Supplier's Guide [2026]

China is the world's second-largest medical device market, valued at approximately USD 60 billion and growing at 12-15% annually. With over 35,000 hospitals and ambitious government plans to upgrade healthcare infrastructure, China offers unparalleled scale. However, the regulatory pathway through NMPA, the volume-based procurement (VBP) program that drives aggressive price competition, and the requirement for a Chinese legal agent make this one of the most complex markets to navigate.

Regulatory authority and approval pathway

The National Medical Products Administration (NMPA) regulates medical devices, with technical review conducted by the Center for Medical Device Evaluation (CMDE):

• Device classification: China uses a three-class system (Class I, II, III). Class I devices require filing (bei'an); Class II require provincial NMPA registration; Class III require national NMPA registration.
• Registration certificate: The NMPA Registration Certificate is the gateway to the Chinese market. Class III registration involves CMDE technical review, clinical evaluation, and quality system assessment — typically 18-36 months.
• Clinical trials: NMPA may require Chinese clinical trial data for novel devices or where international data is insufficient. China has implemented MAH (Marketing Authorization Holder) reforms allowing foreign-held registrations through Chinese legal agents.
• Chinese legal agent: Foreign manufacturers must appoint a Chinese agent who serves as the legal entity on the registration certificate.
• Type testing: Products must undergo testing at NMPA-designated Chinese testing laboratories. International test reports are generally not accepted.

NMPA does not recognize FDA clearance, CE marking, or other foreign approvals. Every device requires independent Chinese registration.

Key procurement platforms and channels

• Volume-Based Procurement (VBP/Centralized Procurement): China's national VBP program — originally for pharmaceuticals, now expanding to medical devices — uses centralized tendering to negotiate dramatically lower prices in exchange for guaranteed purchase volumes. VBP has reduced prices on high-value consumables (coronary stents, orthopedic implants) by 80-90%.
• Provincial procurement platforms: Each of China's 31 provinces operates procurement platforms for public hospital purchasing. Tenders are published on provincial healthcare security administration (yibao ju) websites.
• China Government Procurement Network: National portal for government procurement tenders, including healthcare equipment.
• Hospital-level procurement: Large hospitals (Class 3A — the highest tier) may conduct direct procurement for specialized equipment outside centralized programs.
• GPOs and distribution networks: Sinopharm, China Resources Pharmaceutical, and Shanghai Pharmaceuticals dominate medical device distribution.

Compliance requirements for tenders

• Valid NMPA registration certificate: Mandatory for all procurement participation.
• Chinese-language documentation: All regulatory submissions, tender responses, labeling, and IFU must be in Simplified Chinese.
• National Reimbursement Drug List (NRDL) and device catalogs: Inclusion in reimbursement catalogs determines hospital willingness to purchase.
• GB standards: Compliance with Chinese national standards (Guobiao — GB) is mandatory for many device categories, in addition to international standards.
• Cybersecurity review: Connected medical devices require cybersecurity registration review by NMPA since 2022.

Market size and opportunity

• County-level hospital upgrades: Government programs to equip 2,000+ county-level hospitals with advanced diagnostic and surgical equipment.
• Domestic innovation policy: China actively promotes domestic device manufacturers, but innovative foreign technologies still command premium positioning.
• IVD and molecular diagnostics: Rapid growth in in-vitro diagnostics, particularly at the point-of-care level.
• Rehabilitation and elderly care: Aging population (280 million over 60 by 2030) drives demand for rehabilitation, mobility, and home care devices.

Tips for foreign suppliers

1. Prepare for VBP impact: If your product category enters VBP, prices will drop dramatically. Build a China pricing strategy that accounts for volume commitments and margin compression.
2. Invest in Chinese clinical data: NMPA increasingly requires Chinese clinical evidence. Include Chinese investigational sites in global trials or plan dedicated bridging studies.
3. Select your Chinese agent strategically: Your agent controls your registration and has significant influence over your commercial strategy. Choose a partner with NMPA expertise and distribution capability.
4. Factor in testing timelines: NMPA-designated lab testing adds 6-12 months to the registration timeline. Submit samples early.
5. Monitor provincial tenders systematically: With 31 provinces each running separate procurement, comprehensive tender tracking requires automation. MedStrato tracks Chinese provincial tenders across all platforms. Book a demo to see how.